close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

6.24 -0.48

Strong Buy

Prijsupdate 19 jan 2026, 14:31 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.24

Max

6.24

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-3.82

Winstmarge

-75.213

Werknemers

279

EBITDA

1.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+121.87% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

48M

150M

Vorige openingsprijs

6.72

Vorige sluitingsprijs

6.24

Nieuwssentiment

By Acuity

50%

50%

170 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 jan 2026, 16:17 UTC

Acquisities, Fusies, Overnames

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

DJ

Lezen

19 jan 2026, 23:50 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

DJ

Lezen

19 jan 2026, 23:42 UTC

Marktinformatie

Gold Edges Lower on Likely Technical Correction -- Market Talk

DJ

Lezen

19 jan 2026, 22:29 UTC

Marktinformatie

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

DJ

Lezen

19 jan 2026, 22:29 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

19 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

19 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

19 jan 2026, 21:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

DJ

Lezen

19 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

19 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

19 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

DJ

Lezen

19 jan 2026, 17:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

19 jan 2026, 17:09 UTC

Marktinformatie

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

DJ

Lezen

19 jan 2026, 16:18 UTC

Marktinformatie

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

DJ

Lezen

19 jan 2026, 16:12 UTC

Marktinformatie

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

DJ

Lezen

19 jan 2026, 16:06 UTC

Acquisities, Fusies, Overnames

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

DJ

Lezen

19 jan 2026, 16:04 UTC

Acquisities, Fusies, Overnames

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

DJ

Lezen

19 jan 2026, 16:03 UTC

Acquisities, Fusies, Overnames

LVMH, CTG Duty-Free Also Entered Into a MoU

DJ

Lezen

19 jan 2026, 16:02 UTC

Acquisities, Fusies, Overnames

LVMH: Subscription to Be Made Upon Completion of Transaction

DJ

Lezen

19 jan 2026, 16:00 UTC

Acquisities, Fusies, Overnames

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

DJ

Lezen

19 jan 2026, 16:00 UTC

Marktinformatie

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

DJ

Lezen

19 jan 2026, 15:58 UTC

Acquisities, Fusies, Overnames

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

DJ

Lezen

19 jan 2026, 15:57 UTC

Acquisities, Fusies, Overnames

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

DJ

Lezen

19 jan 2026, 15:57 UTC

Acquisities, Fusies, Overnames

LVMH: Proceeds of Transaction Will Be Paid in Cash

DJ

Lezen

19 jan 2026, 15:56 UTC

Acquisities, Fusies, Overnames

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

DJ

Lezen

19 jan 2026, 15:53 UTC

Acquisities, Fusies, Overnames

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

DJ

Lezen

19 jan 2026, 15:52 UTC

Acquisities, Fusies, Overnames

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

DJ

Lezen

19 jan 2026, 15:51 UTC

Acquisities, Fusies, Overnames

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

DJ

Lezen

19 jan 2026, 15:39 UTC

Marktinformatie

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

DJ

Lezen

19 jan 2026, 15:37 UTC

Marktinformatie

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

121.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14 USD  121.87%

Hoogste 19 USD

Laagste 10 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

170 / 361 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

MDT

Medtronic PLC

96.72

↓-0.11%

A

Agilent Technologies Inc

139.6

↓-0.01%

VEEV

Veeva Systems Inc

222.15

↓-0.07%

HQY

HealthEquity Inc

85.02

↓0%

NEOG

Neogen Corp

9.23

↓-0.11%
help-icon Live chat